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regulates expression of various genes that mediate cellular response to
xenobiotics. The exact functional role of two AHR single nucleotide
polymorphisms (SNPs); Arginine554Lysine (Arg554Lys) and Valine570Isoleu-
cine (Val570Ile) has not yet been established, however studies suggest that these
mutations might increase risk of developing PAs. To date, functional analysis of
regarding the significance of these AHR SNPs in pituitary pathophysiology has
never been analysed.
Aims
† Elucidate the effect of wildtype and polymorphic AHR on GH3 cell
proliferation and on AHR-transcriptional response in the presence and absence
of TCDD.
† Determine the allele frequency of the most common AHR SNP; the Arg554Lys
in PA patients and in a small cohort of the Maltese population.
Method
The two missense mutations were introduced within the AHR-expressing vector
and transfected in GH3 cells by magnetofaction, followed by the exposure to
TCDD. Cell viability of GH3 transfected cells was measured using the MTT
assay. Functional analysis of GH3 transfected cells treated with TCDD was
carried out using luciferase assay and real-time PCR to detect and quantify the
AHR-transcriptional activity. Genotyping of the Arg554Lys was performed on
PA patients and neonatal controls using allele specific PCR. The Mann-Whitney
test was used to compare two groups and Kruskall-Wallis test was used to
compare three groups or more.
Results
In the absence and presence of low TCDD concentrations (1 and 10 nM), over-
expression of wildtype AHR (wtAHR) did not affect GH3 cell proliferation. GH3
cells transfected with the AHR mutants did not exhibit any significant differences
in their proliferative ability when compared with the wtAHR, both in the presence
and absence of TCDD. Luciferase reporter analysis showed that there was a
significant difference between the treated and untreated wtAHR (PZ0.016),
however this difference was not observed between the treated and untreated AHR
mutants. Statistically significant difference in Cyp1a1 gene expression analysis
was detected between the treated and untreated wtAHR (PZ0.021), Arg554Lys
(PZ0.005) and Val570Ile (PZ0.054). Genotyping of the Arg554Lys in patients
with PA gave a minor allele frequency (MAF) of 3% vs 0% in neonatal controls.
Conclusion
Gene expression and quantification analyses of AHR-target genes suggests that
these AHR mutants might interfere with AHR target gene expression. Genotyping
results suggested that this mutation is quite rare and may be similar to the
frequencies of other European populations.
DOI: 10.1530/endoabs.56.P777
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Comparative differential effects of secretagogues upon regulation of
pituitary GH in several vertebrates
Valeria Alejandra Urban Sosa1, Jose´ A´vila Mendoza2,
Martha Carranza Salas1, Carlos Guillermo Martı´nez Moreno1,
Maricela Luna Mun˜oz1 & Carlos Ara´mburo1
1Universidad Nacional Auto´noma de Me´xico, Instituto de Neurobiologı´a,
Quere´taro, Mexico; 2University of Michigan, Ann Arbor, USA.
It is known that the synthesis and release of pituitary GH is controlled by complex
neuroendocrine mechanisms that involve several neuropeptides, such as GHRH,
SST, PACAP, TRH, GnRH, Ghrelin, among other regulators. Previous reports
indicate that, during vertebrate evolution, the potency and efficacy of these
secretagogues may vary and play differential effects upon GH regulation. In this
work we aimed to study, in vitro, the capacity of these peptides to control the
expression and secretion of pituitary GH in three vertebrate models: rat
(mammals), chicken (birds) and iguana (reptiles), employing pituitary cultures
at different incubation periods (0–6 h) and two doses of the secretagogues (1 and
10 nM). Results showed that GHRH significantly stimulated GH mRNA
expression as well as GH secretion in the three species within the first hour of
incubation, in comparison to the controls. However, its effect upon GH mRNA
was 60 times greater in iguana than in the other species. TRH had no effect on GH
secretion in any incubation period, but it stimulated GH mRNA expression in all
species and, in the case of iguana, its effect was 150 times higher than in the
others. PACAP stimulated GH mRNA expression at 4 h in chicken pituitary
cultures, whereas no significant differences were observed in rats and iguanas.
Ghrelin increased GH secretion in chickens, but had no effect in its mRNA
synthesis, contrary to what was found in iguana cultures where GH mRNA
significantly diminished. GnRH stimulated both GH mRNA expression and GH
release in chicken pituitary cultures, while in iguana only GH secretion was
significantly increased. On the other hand, SST strongly inhibited GH mRNA
expression and GH release in the iguana, while no significant effect was directly
observed in rats and chickens, at the doses and time-frame conditions employed.
Results indicate that there is a differential effect of these secretagogues upon GH
synthesis and secretion during vertebrate evolution, and further studies are needed
to understand how these mechanisms have evolved.
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Next generation sequencing for characterization of mitochondrial
genome in pituitary adenomas
Kinga Ne´meth1, Otto´ Darvasi2, Istva´n Liko´2, Nikolette Szu¨cs1,
Sa´ndor Czirja´k3, Lilla Reiniger4, Borba´la Szabo´5, Pe´ter Igaz1,
Attila Pato´cs2,5 & Henriett Butz2,5
12nd Department of Medicine, Faculty of Medicine, Semmelweis
University, Budapest, Hungary; 2MTA-SE ‘Lendulet’ Hereditary Endocrine
Tumors Research Group, Hungarian Academy of Sciences and Semmelweis
University, Budapest, Hungary; 3National Institute of Clinical
Neurosciences, Budapest, Hungary; 41st Department of Pathology and
Experimental Cancer Research, Semmelweis University, Budapest,
Hungary; 5Department of Laboratory Medicine, Semmelweis University,
Budapest, Hungary.
Introduction
Disrupted mitochondrial functions and genetic variations of mitochondrial DNA
(mtDNA) have been observed in different tumors. Regarding pituitary adenomas
mtDNA was evaluated only in oncocytic type using PCR based methods and it
showed high prevalence of Complex I variants. Next generation sequencing
(NGS) allows high throughput sequencing and it is useful for accurate
identification of heteroplasmy of mitochondrial genome as well.
Aim
We aimed to investigate the entire mitochondrial genome in different adenoma
types.
Material and methods
We collected 22 gonadotroph (GO), 11 GH producing (GH) and 11 null-cell (NC)
adenoma specimens from samples removed by transsphenoidal surgery. From
fresh frozen tissues DNA extraction was performed using QIAamp Fast DNA
Tissue Kit. For library preparation VariantPro Amplicon Mitochondrion Panel kit
was used. The total mtDNA (16569 bp) was sequenced on Illumina MiSeq
Instrument. Following complex bioinformatic analysis Revised Cambridge
Reference Sequence (rCRS) of the human mitochondrial DNA was used as
reference. Heteroplasmy was determined using 3% cutoff.
Results
The whole mitochondrial genome were covered by 630G370 (avgGS.E.) reads
per base. 496 variants were identified in adenomas compared to reference
sequence. Overall a low (7.22%) heteroplasmy prevalence was found. Based on
mitochondrial sequence variants by hierarchical cluster analysis we could not
discriminate different adenoma types. No association between Ki-67 index or
recurrent-nonrecurrent status of adenomas and mitochondrial variants were
detected. Four variants appeared more often in null-cell adenomas compared to
gonadotroph adenomas (chrM_188: 18% vs 0%, chrM_16093: 18% vs 0%,
chrM_185: 27% vs 0% and chrM_14798: 36% vs 5%; PadjZ0.0246, 0.0246,
0.01542 and 0.01829, respectively). Of these variants chrM_14798, chrM_4216
and chrM_15452 are non-synonymous polymorphisms leading to amino acid
change in MT-CYB (mitochondrially encoded cytochrome b) and in MT-ND1
(mitochondrially encoded NADH dehydrogenase 1) genes. We identified
chrM_16189 variant (non-protein coding variant) in 40% (6/15) of nonrecurrent
adenomas compared to recurrent ones where this variant was not present (0/11)
(PZ0.0209).
Conclusions
Next-generation sequencing is a reliable method for investigating mitochondrial
genome and heteroplasmy in pituitary adenomas. In pituitary adenomas the
prevalence of heteroplasmy of mitochondrial genome is low suggesting that these
alterations may not influence mitochondrial function considerably. Of pituitary
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tumours only null cell adenomas possess alterations of mitochondrial genome
with potential functional consequences suggesting that during the development of




Pituitary cell activation and recruitment in hipothyroidism
Fernando Oroz, Montserrat Garcı´a-Lavandeira, Sihara Pe´rez-Romero,
A´ngela Garcı´a-Rendueles & Clara V A´lvarez
Center for Research in Molecular Medicine and Chronic Diseases (CiMUS),
Santiago de Compostela, Spain.
Pituitary stem cells have been characterized in the postnatal pituitary. We now
know they are organized in a niche and co-express specific markers such as Sox2,
Sox9 or Gfra2. Although many studies by our group and others have been
dedicated to its characterization in situ it is under discussion their role in the
maintenance and turnover of the pituitary in physiological conditions or
physiological pituitary challenges. It’s not known if the stem cells are required
and which molecular mechanisms are implicated in recruitment/differentiation.
We established a model of hypothyroidism in rodents similar to human conditions
in which levels of thyroxine are maintained just below the lower normal cut-off.
We studied pituitary extracts in a precise time-course for stem cell and
differentiation markers of thyrotropes. We have found that Shh is increased
immediately after the establishing of the hypothyroidism. Following this, we
purified the Gfra2C stem cell population from vehicle and short-term
hypothyroid animals and grown them as spheres in absence of serum. Spheres
grow during the days of culture duplicating from day 1 to day 5 when they reach a
plateau. Gfra2C cells obtained from hypothyroid animals produce a significantly
higher level of spheres per well both at day 1 and at day 5. When cultured in
presence of cyclopamine, a Shh inhibitor, the number of spheres is significantly
reduced in the hypothyroid Gfra2C but not in the control wells. We used
immunofluorescence techniques to see what happen in the intact pituitary niche
in vivo. A genetic mouse model of tracing where Gfra2/Sox2 positive cells are
induced to express GFP long-term after the tamoxifen injection was followed in a
time-course under the same conditions of above vehicle/hypothyroidism. There
was a significant increase of the Sox2 positive cell in long-term hypothyroid mice
compared with vehicle treated. Tracing the GFPC population through a time-
course, we detected a significant increase in the double GFP/TSHC cells in the
adenopituitary of hypothyroid mice compared to vehicle treated. This data
confirm that Sox2 positive cells recruited from the pituitary niche are able to
differentiate into TSH producing cells. In summary, our results indicate that the
Gfra2/Sox2 population, the pituitary stem cells, are activated when a mild
hypothyroidism is induced. Results in vitro and in vivo confirm that initially
(short-term hypothyroidism) the stem cells are driven to proliferate and expand
while later (long-term hypothyroidism) differentiate into thyrotropes.
DOI: 10.1530/endoabs.56.P780
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SOM230 exerts anti-proliferative actions by reducing phospho-ERK1/2
levels in ACTH-secreting pituitary tumour cells
Donatella Treppiedi, Erika Peverelli, Elena Giardino, Rosa Catalano,
Federica Mangili, Maura Arosio & Giovanna Mantovani
Endocrine Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico; Department of Clinical Sciences and Community Health,
University of Milan, Milan, Italy.
Currently, the multi-ligand somatostatin (SS) analogue pasireotide (SOM230) is
the only pituitary-targeted drug used to treat patients with Cushing’s disease.
SOM230 displays the highest affinity to somatostatin receptor type 5 (SSTR5) and
compared to octreotide resulted more effective in reducing ACTH release.
Despite its anti-secretory role, SOM230 has been associated with tumor shrinkage
in patients subjected to long term treatment, although to date the key factors
involved are poor elucidated. The present work aimed to investigate the molecular
mechanisms implicated in SOM230-induced cytostatic and cytotoxic effects in
ACTH-secreting primary tumour cultures and murine corticotroph tumour cells
line, AtT-20. First, by western blot we found SSTR5 expressed at comparable
levels in 17 different ACTH-secreting pituitary samples, whereas SSTR2 was
detectable in 15 out of 17 tissues. SSTR5 and SSTR2 were expressed in AtT-20
cells. Then, we tested the effect of 96h stimulation with 1 mM SOM230 on cell
proliferation in 6 different ACTH-secreting tumors by measuring 5-bromo-
20-deoxyuridine incorporation during DNA synthesis. We found a significant
in vitro suppression of cell growth in half of the analyzed samples (K12.1G
4.3%, P!0.01). Accordingly, SOM230 significantly inhibited cell growth in a
dose-dependent manner in AtT-20 cells (K10.5G7.7% at 10 nM, P!0.05;
K3.9G10.9% at 100nM, P!0.05; K26.8G8.9% at 1 mM, P!0.01), whilst
octreotide was effective only at 1 mM (K13.3G9.1%, P!0.05). To investigate
whether direct antiproliferative actions SOM230-mediated might involve MAPK
and cyclins pathways, we evaluated the expression level of phospho-ERK1/2 and
CD1 in ACTH-secreting primary cultures exposed to 1 mM of SOM230. SOM230
reduced phospho-ERK1/2 levels in 5 of 8 tumours tested (K36.4G20.5%,
P!0.01), whereas no significant difference was found in CD1 expression levels
in 3 tumours. These data were further confirmed in AtT-20 cells, where octreotide
did not have any effect. Furthermore, we found that 48h incubation with 1 mM
SOM230 was able to induce a significant increase of caspase 3/7 activity in 2 of 4
ACTH-secreting primary cultures (17G3.6%, P!0.05). Altogether these data
suggest a downstream implication of phospho-ERK1/2 inhibition in ACTH-
secreting pituitary tumour cells by SOM230 resulting in cell proliferation
suppression and indicating that broader-spectrum SS analogues may play a
crucial role in the treatment of tumours where the MAPK pathway is
overactivated. Moreover, we describe a pro-apoptotic effect of SOM230.
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Background
The exact mechanism behind the hypersecretion of ACTH and lack of negative
cortisol feedback on POMC regulation in functional corticotroph adenomas
(FCA) is unknown. Silent corticotroph adenomas (SCA) express, but do not
secrete functional ACTH and have lower POMC expression. Using RT-qPCR and
immunohistochemistry, previous studies have identified some POMC-transcrip-
tion factors, regulators and processing enzymes to be differentially expressed
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